<?xml version="1.0" encoding="UTF-8"?>
<p>The transition from CHIKF to CCA is variable. In many patients, arthrialgias/arthritis began at the onset of disease and is unremitting. In others, there is transient improvement after CHIKF followed by persisitent arthritis [
 <xref rid="B4-viruses-11-00289" ref-type="bibr">4</xref>,
 <xref rid="B12-viruses-11-00289" ref-type="bibr">12</xref>,
 <xref rid="B23-viruses-11-00289" ref-type="bibr">23</xref>]. In several studies, 25% to 62% of patients had arthritic symptoms 18 months after the onset of CHIKF [
 <xref rid="B23-viruses-11-00289" ref-type="bibr">23</xref>,
 <xref rid="B24-viruses-11-00289" ref-type="bibr">24</xref>]. Even at the 36-month follow-up, the prevalence of arthritis has been reported to be as high as 60% [
 <xref rid="B12-viruses-11-00289" ref-type="bibr">12</xref>,
 <xref rid="B13-viruses-11-00289" ref-type="bibr">13</xref>,
 <xref rid="B25-viruses-11-00289" ref-type="bibr">25</xref>]. Among 152 Colombian patients evaluated at 26 weeks after disease onset, persistent arthritis was found in 54%, morning stiffness in 49%, joint edema in 41%, and both polyarthralgia and morning stiffness in 38% [
 <xref rid="B26-viruses-11-00289" ref-type="bibr">26</xref>]. In a Reunion Island study (2005–2006) of 88 patients, chronic arthritis occurred in 93%, 57%, and 47% at 3, 15, and 24 months, respectively [
 <xref rid="B24-viruses-11-00289" ref-type="bibr">24</xref>]. In another Colombian cohort (2014–2015), persistent arthritis was less frequent, with 12% affected at the 18-month follow-up [
 <xref rid="B23-viruses-11-00289" ref-type="bibr">23</xref>].
</p>
